ATE508747T1 - C-kit kinase-hemmer - Google Patents
C-kit kinase-hemmerInfo
- Publication number
- ATE508747T1 ATE508747T1 AT04719054T AT04719054T ATE508747T1 AT E508747 T1 ATE508747 T1 AT E508747T1 AT 04719054 T AT04719054 T AT 04719054T AT 04719054 T AT04719054 T AT 04719054T AT E508747 T1 ATE508747 T1 AT E508747T1
- Authority
- AT
- Austria
- Prior art keywords
- kit kinase
- kinase inhibitors
- discovered
- general formula
- inhibitory activity
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 abstract 3
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003062823 | 2003-03-10 | ||
| JP2003302803 | 2003-08-27 | ||
| PCT/JP2004/003087 WO2004080462A1 (ja) | 2003-03-10 | 2004-03-10 | c-Kitキナーゼ阻害剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE508747T1 true ATE508747T1 (de) | 2011-05-15 |
Family
ID=32992931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04719054T ATE508747T1 (de) | 2003-03-10 | 2004-03-10 | C-kit kinase-hemmer |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7994159B2 (de) |
| EP (1) | EP1604665B1 (de) |
| JP (1) | JPWO2004080462A1 (de) |
| AT (1) | ATE508747T1 (de) |
| WO (1) | WO2004080462A1 (de) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100600550B1 (ko) | 2000-10-20 | 2006-07-13 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
| EP1604665B1 (de) | 2003-03-10 | 2011-05-11 | Eisai R&D Management Co., Ltd. | C-kit kinase-hemmer |
| JP4303726B2 (ja) | 2003-11-11 | 2009-07-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウレア誘導体およびその製造方法 |
| HUE025742T2 (hu) | 2003-12-25 | 2016-04-28 | Eisai R&D Man Co Ltd | 4-(3-klór-4-(ciklopropilamino-karbonil)aminofenoxi)-7-metoxi-6-kinolin-karboxamid vagy szolvátja sójának kristálya és eljárás elõállításukra |
| US8969379B2 (en) * | 2004-09-17 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide |
| US8247419B2 (en) * | 2005-06-09 | 2012-08-21 | Bristol-Myers Squibb Company | Methods of identifying and treating individuals exhibiting mutant kit protein |
| KR100951607B1 (ko) * | 2005-06-23 | 2010-04-09 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 4-(3-클로로-4-(시클로프로필아미노카르보닐)아미노페녹시)-7-메톡시-6-퀴놀린카르복사미드의 비정질 염 및 그 제조방법 |
| US7550483B2 (en) | 2005-06-23 | 2009-06-23 | Eisai R&D Management Co., Ltd. | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same |
| JP5066446B2 (ja) * | 2005-08-01 | 2012-11-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を予測する方法 |
| JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
| KR101353763B1 (ko) | 2005-11-07 | 2014-01-21 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 c―kit 키나아제 저해 물질의병용 |
| US20090247576A1 (en) * | 2005-11-22 | 2009-10-01 | Eisai R & D Management Co., Ltd. | Anti-tumor agent for multiple myeloma |
| CN104706637A (zh) * | 2006-05-18 | 2015-06-17 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
| US20090203693A1 (en) | 2006-06-29 | 2009-08-13 | Eisai R & D Management Co., Ltd. | Therapeutic agent for liver fibrosis |
| JP5368096B2 (ja) | 2006-08-28 | 2013-12-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 未分化型胃癌に対する抗腫瘍剤 |
| WO2008115300A1 (en) * | 2006-12-01 | 2008-09-25 | Apocell, Inc. | C-kit phosphorylation in cancer |
| WO2008093855A1 (ja) | 2007-01-29 | 2008-08-07 | Eisai R & D Management Co., Ltd. | 未分化型胃癌治療用組成物 |
| CA2704000C (en) | 2007-11-09 | 2016-12-13 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
| WO2009096377A1 (ja) * | 2008-01-29 | 2009-08-06 | Eisai R & D Management Co., Ltd. | 血管阻害物質とタキサンとの併用 |
| CA2771403C (en) * | 2009-08-19 | 2015-02-24 | Eisai R&D Management Co. Ltd. | Quinoline derivative-containing pharmaceutical composition |
| CN102958523B (zh) | 2010-06-25 | 2014-11-19 | 卫材R&D管理有限公司 | 使用具有激酶抑制作用的组合的抗肿瘤剂 |
| AU2012246490B2 (en) | 2011-04-18 | 2016-08-04 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
| JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
| ES2573831T3 (es) | 2011-07-27 | 2016-06-10 | Ab Science | Derivados de oxazol y tiazol como inhibidores selectivos de la proteína quinasa (C-kit) |
| JPWO2014098176A1 (ja) * | 2012-12-21 | 2017-01-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体のアモルファス及びその製造方法 |
| CA2912219C (en) | 2013-05-14 | 2021-11-16 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| EP3187491A4 (de) | 2014-08-28 | 2018-08-01 | Eisai R&D Management Co., Ltd. | Hochreines chinolinderivat und verfahren zur herstellung davon |
| US20180028662A1 (en) | 2015-02-25 | 2018-02-01 | Eisai R&D Management Co., Ltd. | Method for Suppressing Bitterness of Quinoline Derivative |
| KR20240064733A (ko) | 2015-03-04 | 2024-05-13 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| CA2988707C (en) | 2015-06-16 | 2023-10-10 | Eisai R&D Management Co., Ltd. | Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer |
| CN108135894B (zh) | 2015-08-20 | 2021-02-19 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
| CN110072528B (zh) | 2017-02-08 | 2022-04-26 | 卫材R&D管理有限公司 | 治疗肿瘤的药物组合物 |
| WO2018157411A1 (zh) * | 2017-02-28 | 2018-09-07 | 深圳市塔吉瑞生物医药有限公司 | 取代的含氮芳环化合物及其应用 |
| WO2018212202A1 (en) | 2017-05-16 | 2018-11-22 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
| WO2019222075A1 (en) | 2018-05-14 | 2019-11-21 | Merck Sharp And Dohme Corp. | Biomarkers for a combination therapy comprising lenvatinib and a pd-1 antagonist |
| CN110845408A (zh) * | 2018-08-20 | 2020-02-28 | 润佳(苏州)医药科技有限公司 | 同位素富集的乐伐替尼 |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| CN115362003B (zh) | 2019-12-24 | 2024-03-22 | 卡尔那生物科学株式会社 | 二酰基甘油激酶调节化合物 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| TWI890283B (zh) | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ, インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| CN117355531A (zh) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| EP4359413A1 (de) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercolkinase modulierende verbindungen |
| CN113480479B (zh) * | 2021-08-12 | 2022-08-02 | 上海爱博医药科技有限公司 | 脲类多靶点酪氨酸激酶抑制剂及其医药应用 |
| EP4423078A1 (de) | 2021-10-28 | 2024-09-04 | Gilead Sciences, Inc. | Pyrizidin-3(2h)-on-derivate |
| PE20241186A1 (es) | 2021-10-29 | 2024-06-03 | Gilead Sciences Inc | Compuestos de cd73 |
| CN118488948A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| US20240124412A1 (en) | 2021-12-22 | 2024-04-18 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CA3248911A1 (en) | 2022-01-28 | 2023-08-03 | Gilead Sciences, Inc. | POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS |
| PL4245756T3 (pl) | 2022-03-17 | 2025-02-17 | Gilead Sciences, Inc. | Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania |
| EP4511127A1 (de) | 2022-04-21 | 2025-02-26 | Gilead Sciences, Inc. | Kras-g12d-modulierende verbindungen |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| EP4638436A1 (de) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5-inhibitoren und verwendungen davon |
| WO2024215754A1 (en) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| PE20260121A1 (es) | 2023-04-21 | 2026-01-16 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| JP2026522894A (ja) | 2023-06-30 | 2026-07-09 | ギリアード サイエンシーズ, インコーポレイテッド | Kras調節化合物 |
| AU2024297978A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| CN121568935A (zh) | 2023-07-26 | 2026-02-24 | 吉利德科学公司 | Parp7抑制剂 |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| EP4774280A1 (de) | 2023-09-08 | 2026-07-15 | Gilead Sciences, Inc. | Kras-g12d-modulierende verbindungen |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20260098049A1 (en) | 2024-08-12 | 2026-04-09 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20260130893A1 (en) | 2024-10-21 | 2026-05-14 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026136515A1 (en) | 2024-12-19 | 2026-06-25 | Gilead Sciences, Inc. | Parp7 inhibitors |
Family Cites Families (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
| DE3587022T2 (de) | 1984-02-17 | 1993-06-17 | Genentech Inc | Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren. |
| DE8411409U1 (de) | 1984-04-11 | 1984-08-30 | Dr.-Ing. Walter Frohn-Betriebe, 8000 München | Entgasungsventil fuer lager- und/oder transportbehaelter |
| DE3587500T2 (de) | 1984-12-04 | 1993-12-16 | Lilly Co Eli | Tumorbehandlung bei Säugetieren. |
| JPS62168137A (ja) * | 1985-12-20 | 1987-07-24 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料およびその処理方法 |
| JPH07106295B2 (ja) | 1986-07-22 | 1995-11-15 | エーザイ株式会社 | 調湿剤 |
| CA1339136C (en) | 1987-07-01 | 1997-07-29 | Sailesh Amilal Varia | Amorphous form of aztreonam |
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US4983615A (en) | 1989-06-28 | 1991-01-08 | Hoechst-Roussel Pharmaceuticals Inc. | Heteroarylamino- and heteroaryloxypyridinamine compounds which are useful in treating skin disorders |
| US5180818A (en) | 1990-03-21 | 1993-01-19 | The University Of Colorado Foundation, Inc. | Site specific cleavage of single-stranded dna |
| GB9105677D0 (en) | 1991-03-19 | 1991-05-01 | Ici Plc | Heterocyclic compounds |
| US5367057A (en) | 1991-04-02 | 1994-11-22 | The Trustees Of Princeton University | Tyrosine kinase receptor flk-2 and fragments thereof |
| JPH04341454A (ja) | 1991-05-16 | 1992-11-27 | Canon Inc | シート収納装置 |
| US5750376A (en) | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
| JPH08501203A (ja) | 1992-06-03 | 1996-02-13 | ケイス・ウエスタン・リザーブ・ユニバーシティー | 生理活性物質を連続的に適用するための包帯 |
| JPH06153952A (ja) | 1992-11-26 | 1994-06-03 | Nobuaki Tamamaki | 微量未知二重鎖dna分子の増幅、標識を行うための前処理方法 |
| GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
| JPH07176103A (ja) | 1993-12-20 | 1995-07-14 | Canon Inc | 光磁気記録再生システムならびにこれに用いる磁気ヘッド及び光磁気記録媒体 |
| GB9326136D0 (en) | 1993-12-22 | 1994-02-23 | Erba Carlo Spa | Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents |
| US6811779B2 (en) | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
| JP3660391B2 (ja) | 1994-05-27 | 2005-06-15 | 株式会社東芝 | 半導体装置の製造方法 |
| JPH0848078A (ja) | 1994-08-05 | 1996-02-20 | Nippon Paper Ind Co Ltd | 感熱記録体 |
| US5656454A (en) | 1994-10-04 | 1997-08-12 | President And Fellows Of Harvard College | Endothelial cell-specific enhancer |
| IL115256A0 (en) | 1994-11-14 | 1995-12-31 | Warner Lambert Co | 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use |
| US5658374A (en) | 1995-02-28 | 1997-08-19 | Buckman Laboratories International, Inc. | Aqueous lecithin-based release aids and methods of using the same |
| US5624937A (en) | 1995-03-02 | 1997-04-29 | Eli Lilly And Company | Chemical compounds as inhibitors of amyloid beta protein production |
| ATE446955T1 (de) | 1995-03-30 | 2009-11-15 | Pfizer Prod Inc | Chinazolinone derivate |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| JPH0923885A (ja) | 1995-07-12 | 1997-01-28 | Dai Ichi Seiyaku Co Ltd | 遺伝子発現ライブラリー及びその製造法 |
| US6346398B1 (en) | 1995-10-26 | 2002-02-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
| DE69622183D1 (de) | 1995-11-07 | 2002-08-08 | Kirin Brewery | Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen |
| GB9604361D0 (en) | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
| JPH09234074A (ja) | 1996-03-04 | 1997-09-09 | Sumitomo Electric Ind Ltd | アダプター二本鎖dna及びそれを用いたdna増幅方法 |
| EP0837063A1 (de) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazolinderivate |
| US6090556A (en) | 1997-04-07 | 2000-07-18 | Japan Science & Technology Corporation | Method for quantitatively determining the expression of a gene |
| AU8283898A (en) | 1997-06-30 | 1999-01-25 | University Of Maryland At Baltimore | Heparin binding-epidermal growth factor in the diagnosis of interstitial cystitis |
| JP3765918B2 (ja) | 1997-11-10 | 2006-04-12 | パイオニア株式会社 | 発光ディスプレイ及びその駆動方法 |
| IL144461A0 (en) | 1999-01-22 | 2002-05-23 | Kirin Brewery | Quinoline and quinazoline derivatives and pharmaceutical compositions containing them |
| JP3270834B2 (ja) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
| EE05345B1 (et) | 1999-02-10 | 2010-10-15 | Astrazeneca Ab | Kinasoliini derivaadid angiogeneesi inhibiitoritena |
| JP2000328080A (ja) | 1999-03-12 | 2000-11-28 | Shin Etsu Chem Co Ltd | シートベルト用低摩擦化処理剤 |
| YU13200A (sh) | 1999-03-31 | 2002-10-18 | Pfizer Products Inc. | Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja |
| EP1179541B1 (de) | 1999-04-28 | 2004-06-16 | Board Of Regents, The University Of Texas System | Zusammensetzungen und Verfahren zur Krebsbehandlung durch die selektive Hemmung von VEGF |
| WO2001012600A1 (en) | 1999-08-12 | 2001-02-22 | Cor Therapeutics, Inc. | INHIBITORS OF FACTOR Xa |
| JP2001131071A (ja) | 1999-10-29 | 2001-05-15 | Meiji Seika Kaisha Ltd | 非晶質および非晶質を含有する医薬組成物 |
| JP2003525595A (ja) | 1999-11-01 | 2003-09-02 | キュラゲン コーポレイション | 脈管形成に含まれる差動発現遺伝子、それにコードされるポリペプチド、及びそれを用いた方法 |
| CA2395461C (en) * | 1999-12-22 | 2010-05-25 | Sugen, Inc. | Methods of modulating c-kit tyrosine kinase function with indolinone compounds |
| EP1243582A4 (de) | 1999-12-24 | 2003-06-04 | Kirin Brewery | Chinolin- und chinazolinderivate sowie medikamente, die diese enthalten |
| DE60018216T2 (de) | 1999-12-24 | 2006-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Kondensierte purinderivate |
| HRP20020751B1 (hr) | 2000-02-15 | 2011-01-31 | Sugen | Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze |
| JP3657203B2 (ja) | 2000-04-21 | 2005-06-08 | エーザイ株式会社 | 銅クロロフィリン塩含有液剤組成物 |
| CA2409044C (en) * | 2000-05-15 | 2013-02-19 | Takeda Chemical Industries, Ltd. | Improved recrystallization processes for obtaining anhydrous optically active lansoprazole |
| WO2001096390A2 (en) | 2000-06-09 | 2001-12-20 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of colon cancer |
| KR100600550B1 (ko) | 2000-10-20 | 2006-07-13 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
| TWI283575B (en) | 2000-10-31 | 2007-07-11 | Eisai Co Ltd | Medicinal compositions for concomitant use as anticancer agent |
| AU2002223684A1 (en) | 2000-11-22 | 2002-06-03 | Novartis Pharma Gmbh | Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity |
| WO2002072578A2 (en) * | 2001-03-08 | 2002-09-19 | Millennium Pharmaceuticals | (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases |
| JP3602513B2 (ja) | 2001-04-27 | 2004-12-15 | 麒麟麦酒株式会社 | アゾリル基を有するキノリン誘導体およびキナゾリン誘導体 |
| EP1382604B1 (de) | 2001-04-27 | 2005-12-28 | Kirin Beer Kabushiki Kaisha | Chinolinderivate mit einer azolylgruppe und chinazolinderivate |
| JP2003026576A (ja) | 2001-05-09 | 2003-01-29 | Eisai Co Ltd | 味覚改善製剤 |
| AU2002342335B2 (en) | 2001-05-16 | 2006-02-02 | Novartis Ag | Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent |
| GB0119467D0 (en) | 2001-08-09 | 2001-10-03 | Smithkline Beecham Plc | Novel compound |
| EP1451348B1 (de) | 2001-09-10 | 2015-08-12 | Meso Scale Technologies, LLC | Verfahren, reagentien, kits und vorrichtungen zur proteinfunktionsanalyse |
| CA2460845A1 (en) * | 2001-09-20 | 2003-03-27 | Ab Science | Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis |
| US20040266779A1 (en) | 2001-09-27 | 2004-12-30 | Anderson Kenneth C. | Use of c-kit inhibitors for the treatment of myeloma |
| JP2005531488A (ja) | 2001-10-09 | 2005-10-20 | ザ・ユニバーシティ・オブ・シンシナティ | 甲状腺癌を処置するためのegf受容体阻害剤 |
| JP4383870B2 (ja) | 2001-10-17 | 2009-12-16 | 協和発酵キリン株式会社 | 線維芽細胞増殖因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物 |
| WO2003074045A1 (en) | 2002-03-05 | 2003-09-12 | Eisai Co., Ltd. | Antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with angiogenesis inhibitor |
| EP1488239A2 (de) | 2002-03-20 | 2004-12-22 | Dana-Farber Cancer Institute, Inc. | Verfahren und verbindungen für die identifizierung, nachweis und behandlung von kleinzellen-lungenkarzinom |
| JPWO2003093238A1 (ja) | 2002-05-01 | 2005-09-08 | 麒麟麦酒株式会社 | マクロファージコロニー刺激因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体 |
| UA77303C2 (en) | 2002-06-14 | 2006-11-15 | Pfizer | Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use |
| WO2004006862A2 (en) | 2002-07-16 | 2004-01-22 | Children's Medical Center Corporation | A method for the modulation of angiogenesis |
| US20060004029A1 (en) | 2002-08-30 | 2006-01-05 | Akihiko Tsuruoka | Nitrogen-containing aromatic derivatives |
| BR0315169A (pt) | 2002-10-09 | 2005-08-23 | Kosan Biosciences Inc | Referência cruzada a pedidos de patente relacionados |
| GB0223380D0 (en) | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| JP4749660B2 (ja) | 2002-10-16 | 2011-08-17 | 武田薬品工業株式会社 | 安定な固形製剤 |
| US8697094B2 (en) | 2002-10-16 | 2014-04-15 | Takeda Pharmaceutical Company Limited | Stable solid preparations |
| WO2004039782A1 (ja) * | 2002-10-29 | 2004-05-13 | Kirin Beer Kabushiki Kaisha | Flt3自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物 |
| CA2502979A1 (en) | 2002-11-06 | 2004-05-21 | Cyclacel Limited | Pharmaceutical composition comprising a cdk inhibitor and gemcitabine |
| GB0226434D0 (en) | 2002-11-13 | 2002-12-18 | Astrazeneca Ab | Combination product |
| AR042042A1 (es) | 2002-11-15 | 2005-06-08 | Sugen Inc | Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular |
| US7399866B2 (en) | 2003-01-14 | 2008-07-15 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| MXPA05009434A (es) | 2003-03-05 | 2005-11-23 | Celgene Corp | Compuestos de difeniletileno y usos de los mismos. |
| EP1604665B1 (de) | 2003-03-10 | 2011-05-11 | Eisai R&D Management Co., Ltd. | C-kit kinase-hemmer |
| JPWO2004081047A1 (ja) | 2003-03-14 | 2006-06-29 | 大正製薬株式会社 | モノクローナル抗体及びこれを産生するハイブリドーマ |
| US20070117842A1 (en) | 2003-04-22 | 2007-05-24 | Itaru Arimoto | Polymorph of 4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6- quinolinecarboxamide and a process for the preparation of the same |
| DE602004013792D1 (de) * | 2003-08-15 | 2008-06-26 | Ab Science | Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes |
| EA200600495A1 (ru) | 2003-09-23 | 2006-10-27 | Новартис Аг | Комбинация ингибитора vegf рецептора с химиотерапевтическим агентом |
| EP2210607B1 (de) | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamid zur Behandlung von Krebs |
| JP4303726B2 (ja) | 2003-11-11 | 2009-07-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウレア誘導体およびその製造方法 |
| RU2006122853A (ru) | 2003-11-28 | 2008-01-10 | Новартис АГ (CH) | Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы |
| BRPI0417302A (pt) | 2003-12-05 | 2007-03-06 | Compound Therapeutics Inc | inibidores de receptores de fator de crescimento endotelial vascular do tipo 2 |
| HUE025742T2 (hu) | 2003-12-25 | 2016-04-28 | Eisai R&D Man Co Ltd | 4-(3-klór-4-(ciklopropilamino-karbonil)aminofenoxi)-7-metoxi-6-kinolin-karboxamid vagy szolvátja sójának kristálya és eljárás elõállításukra |
| KR100799534B1 (ko) | 2004-02-27 | 2008-01-31 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 신규 피리딘 유도체 및 피리미딘 유도체(1) |
| KR20050091462A (ko) | 2004-03-12 | 2005-09-15 | 한국과학기술연구원 | 푸로피리미딘 화합물 및 이를 포함하는 ddr2 티로신키나아제 활성 저해제 |
| JP4341454B2 (ja) | 2004-04-08 | 2009-10-07 | トヨタ自動車株式会社 | 固体電解質型燃料電池の製造方法 |
| JP2008501652A (ja) | 2004-06-03 | 2008-01-24 | エフ.ホフマン−ラ ロシュ アーゲー | ゲムシタビン及びegfrインヒビターによる治療 |
| US8772269B2 (en) | 2004-09-13 | 2014-07-08 | Eisai R&D Management Co., Ltd. | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors |
| WO2006030941A1 (ja) | 2004-09-13 | 2006-03-23 | Eisai R & D Management Co., Ltd. | スルホンアミド含有化合物の血管新生阻害物質との併用 |
| US8969379B2 (en) | 2004-09-17 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide |
| US20060079494A1 (en) | 2004-09-27 | 2006-04-13 | Santi Daniel V | Specific kinase inhibitors |
| CA2586420A1 (en) | 2004-11-22 | 2007-04-12 | King Pharmaceuticals Research & Development, Inc. | Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists |
| US7612200B2 (en) | 2004-12-07 | 2009-11-03 | Locus Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| JP5106098B2 (ja) | 2005-02-28 | 2012-12-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スルホンアミド化合物の抗癌剤との新規併用 |
| PL1859793T3 (pl) | 2005-02-28 | 2011-09-30 | Eisai R&D Man Co Ltd | Nowe połączone zastosowanie związku sulfonamidowego w leczeniu choroby nowotworowej |
| US7550483B2 (en) | 2005-06-23 | 2009-06-23 | Eisai R&D Management Co., Ltd. | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same |
| KR100951607B1 (ko) | 2005-06-23 | 2010-04-09 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 4-(3-클로로-4-(시클로프로필아미노카르보닐)아미노페녹시)-7-메톡시-6-퀴놀린카르복사미드의 비정질 염 및 그 제조방법 |
| WO2007014335A2 (en) | 2005-07-27 | 2007-02-01 | The University Of Texas System | Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer |
| JP5066446B2 (ja) | 2005-08-01 | 2012-11-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を予測する方法 |
| JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
| KR101353763B1 (ko) | 2005-11-07 | 2014-01-21 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 c―kit 키나아제 저해 물질의병용 |
| US20090247576A1 (en) | 2005-11-22 | 2009-10-01 | Eisai R & D Management Co., Ltd. | Anti-tumor agent for multiple myeloma |
| CN104706637A (zh) | 2006-05-18 | 2015-06-17 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
-
2004
- 2004-03-10 EP EP04719054A patent/EP1604665B1/de not_active Expired - Lifetime
- 2004-03-10 US US10/797,903 patent/US7994159B2/en not_active Expired - Fee Related
- 2004-03-10 AT AT04719054T patent/ATE508747T1/de not_active IP Right Cessation
- 2004-03-10 WO PCT/JP2004/003087 patent/WO2004080462A1/ja not_active Ceased
- 2004-03-10 JP JP2005503539A patent/JPWO2004080462A1/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2004080462A1 (ja) | 2006-06-08 |
| US7994159B2 (en) | 2011-08-09 |
| EP1604665A4 (de) | 2009-05-13 |
| EP1604665A1 (de) | 2005-12-14 |
| WO2004080462A1 (ja) | 2004-09-23 |
| EP1604665B1 (de) | 2011-05-11 |
| US20040253205A1 (en) | 2004-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1604665A4 (de) | C-kit kinase-hemmer | |
| TW200610531A (en) | Phthalazine derivatives as PARP inhibitors | |
| MX2009012345A (es) | Derivados de 3,3-espiroindolinona. | |
| TW200616978A (en) | Quinazolinone derivatives as parp inhibitors | |
| GEP20094785B (en) | Pyrrolopyrazoles, potent kinase inhibitors | |
| MX2009004766A (es) | Derivados de espiroindolinona. | |
| MX2009002735A (es) | Derivados de oxindol como agentes anticancerigenos. | |
| SG154432A1 (en) | Quinazolinedione derivatives as parp inhibitors | |
| TW200740815A (en) | P38 MAP kinase inhibitors and methods for using the same | |
| TW200618800A (en) | Heterocyclic compounds | |
| TW200642689A (en) | Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient | |
| MX2009004441A (es) | Derivados de indazol utiles como inhibidores de las isoformas de higado. | |
| WO2006084017A3 (en) | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors | |
| MX2007005933A (es) | Compuestos de acetamida como fungicidas. | |
| CY1107846T1 (el) | Παραγωγα κιναζολινονης χρησιμα ως βανιλλοειδεις ανταγωνιστες | |
| TW200833324A (en) | Sulfonamide derivatives | |
| MY153727A (en) | Pyridazinone derivatives | |
| TW200745032A (en) | Novel heterobicyclic derivatives | |
| MX2010009927A (es) | Derivados de espiroindolinona. | |
| GB0308201D0 (en) | Novel compounds | |
| NO20061317L (no) | Imidazopyridinderivater som induserbare NO-syntaseinhibatorer | |
| MY148644A (en) | New pharmaceutical compounds | |
| ATE469647T1 (de) | Thienoä3,2-cüpyridin-7-carbonsäure-derivate | |
| NO20061344L (no) | Imidazopyridinderivater som induserbare NO-syntaseoinhibitorer | |
| DE602004014523D1 (de) | Imidazoä4,5-büpyridinderivate als inhibitoren der induzierbaren no-synthase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |